Iressa Home image1

IRESSA (gefitinib) as a first-line treatment for EGFR mutation-positive advanced NSCLC

IRESSA is a highly convenient, once-daily oral tablet that offers superior progression-free survival, better tolerability and quality of life compared with doublet chemotherapy (carboplatin/paclitaxel) as first-line treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC).

Read more

Over 10 years of real-world experience

IRESSA is a standard of care treatment across multiple countries in adults with EGFR mutation-positive advanced NSCLC, due to its consistent efficacy and differentiated safety profile as demonstrated by four pivotal trials

Read more

Identifying EGFR mutation-positive patients

EGFR is a protein found in abnormally high levels on the surface of many types of cancer cells, particularly NSCLC cells. A patient‘s EGFR mutation status (positive or negative) can be confirmed via a diagnostic test using a sample of tumour tissue or plasma (for circulating tumour DNA testing).

Read more

Shiva
This content is not currently available for your device.

X


References

  1. Cohen MH et al. FDA drug approval summary: gefitinib (ZD1839) (Iressa®) tablets. Oncologist 2003;8:303-306.
  2. AstraZeneca data on file.
  3. Mok TS et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
  4. Mitsudomi T et al; the West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128.
  5. Maemondo M et al; the North-East Japan Study Group. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388.
  6. Douillard J-Y et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer 2014;110:55-62.